Kymera Therapeutics closed at $136.25 on Nov 4, up 7.21% — matching its 52-week closing high. Volume of 1.8M shares was 1.99× its 20-day average (above normal).
Split-adjusted performance: +28.6% over one month, +58.0% over six months, +128.1% over one year.
Short interest was 9.2M shares at the Oct 15 settlement, down 7.5% from the prior report (13.7% of float, 10.0 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| KYMRKymera Therapeutics | $136.25 | +7.21% | +58.0% | −100.0% | — | — | $11.63B | |
| TECHBio-Techne | $72.73 | +0.10% | +53.4% | +1.3% | 17.0% | 62.8 | $11.42B | Compare |
| RGENRepligen | $178.20 | −0.04% | +41.7% | +10.9% | −18.4% | — | $11.31B | Compare |
| PCVXVaxcyte | $65.68 | +8.01% | +15.0% | — | — | — | $10.34B | Compare |
| IBRXImmunityBio | $8.93 | +7.72% | +6.6% | +93.9% | −449.6% | — | $9.46B | Compare |
| TWSTTwist Bioscience | $142.58 | +1.63% | +139.5% | +23.2% | −29.6% | — | $9.45B | Compare |
| KRYSKrystal Biotech | $310.84 | +1.90% | +7.6% | +30.2% | 49.5% | 40.9 | $9.20B | Compare |
| HALOHalozyme Therapeutics | $130.34 | +1.34% | +96.4% | +47.7% | 47.8% | 35.8 | $14.79B | Compare |
| NBIXNeurocrine Biosciences | $166.05 | +0.73% | +12.9% | +41.2% | 18.4% | 24.0 | $16.88B | Compare |
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
